BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) is a publicly traded company in the Unknown sector. Across all available filings, 29 corporate insiders have executed 518 transactions totaling $1.0B, demonstrating a bearish sentiment with -$595.6M in net insider flow. The most recent transaction on Dec 15, 2025 involved a sale of 28,311 shares valued at $2.1M.
BBIO Insider Activity Summary
Who Is Buying BBIO Stock?
No significant insider buying has been recorded for BBIO in the recent period.
Who Is Selling BBIO Stock?
No significant insider selling has been recorded for BBIO in the recent period.
Is BridgeBio Pharma, Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for BBIO is bearish with an Insider Alignment Score of 21/100 and a net flow of -$595.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
BBIO Frequently Asked Questions
Understanding BBIO Insider Activity
Insider trading at BridgeBio Pharma, Inc. (BBIO) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 29 insiders are actively trading BBIO stock, having executed 518 transactions in the past 90 days. The most active insider is Genetic Disorder L.p. Kkr (Executive), who has made 2 transactions totaling $288.4M.
Related Tools
Track BridgeBio Pharma, Inc. Insider Activity
Get notified when executives and directors at BBIO file new Form 4 transactions